Status:
RECRUITING
Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Metastasis Spinal Tumor
Eligibility:
All Genders
10-80 years
Phase:
PHASE1
PHASE2
Brief Summary
Massive blood loss occurs in metastatic spinal tumor resection and may cause severe complications. The objective of this study is to investigate whether the use of tranexamic acid will reduce perioper...
Eligibility Criteria
Inclusion
- Diagnosed as metastatic carcinoma of the thoracolumbar spine
- solitary neoplasm involve only one segment of spine
- patients underwent separation surgery
Exclusion
- coagulation function was abnormal preoperatively
- patients are allergic to tranexamic acid
- neoplasm involve more than one segment of spine
- patients with rich blood supply who need embolization
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06023212
Start Date
December 1 2023
End Date
August 1 2026
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 311200